Tiziana begins phase 1b trial of oral foralumab for Crohn's Disease

Mar. 25, 2022 7:51 AM ETTiziana Life Sciences Ltd (TLSA)By: Ravikash, SA News Editor

Acid reflux or Heartburn, The photo of stomach is on the men"s body against gray Background, Bad health, Male anatomy concept

Tharakorn/iStock via Getty Images

  • Tiziana Life Sciences (NASDAQ:TLSA) began a phase 1b trial to evaluate oral enteric-coated capsules of foralumab in patients with mild-to-moderate Crohn's Disease (CD), a type of inflammatory bowel disease.
  • The company said patient enrollment will begin in Q2.
  • Tiziana noted that the trial, for the first-ever oral immunotherapy for patients with mild-to-moderately active CD, is expected to be completed by Q4.
  • TLSA +4.50% pre-market to $1.16

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.